Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children
NCT ID: NCT00810862
Last Updated: 2008-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
18 participants
INTERVENTIONAL
2006-11-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
NCT00130364
Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis
NCT00351052
Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
NCT00925730
Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis
NCT00121381
5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
NCT00120523
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pimecrolimus
Pimecrolimus 1% cream
pimecrolimus active cream
Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
2
Placebo cream over affected study area
placebo base cream
apply to affected study area twice daily for 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pimecrolimus active cream
Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
placebo base cream
apply to affected study area twice daily for 21 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* mild to moderate atopic dermatitis
Exclusion Criteria
* allergy to Elidel or components
* use of oral steroids, immunosuppressive agents,cytostatics of phototherapy within 4 weeks prior to study.
* previous continuous or non-continuous use of pimecrolimus or tacrolimus for greater than 11 months within 2 weeks of enrollment.
* active skin infections.
* immunocompromised patients.
* previous history of skin cancer or lymphoma
* any hypopigmentation in study areas
* pregnant or breastfeeding
* participation in another investigational trial
2 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Children's Hospital of Michigan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Children's Hospital of Michigan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
pimecrolimus1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.